Priority Review for Paratek's antibiotic

FDA accepted and granted Priority Review to two NDAs from Paratek Pharmaceuticals Inc. (NASDAQ:PRTK) for omadacycline to treat community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSIs). The PDUFA dates are in October; a specific date was not disclosed.

The company said FDA is planning an advisory committee meeting for the NDAs...